RxDoctor Payments Data

Rosaura Baez, MD

Internal Medicine · Venice, FLNPI 1750494555

Payments from drug & device makers

$1,865in general payments, 2019–2025

Across 76 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$871
  • Novo Nordisk$271
  • Lilly USA, LLC$187
  • Nevro Corp.$107
  • GSK$68
  • Novartis$57
  • plus $305 from 13 others

What the payments were for

  • Food & beverage$1,84899%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,865 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$77,430
Medicare patients
201
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$93,491
JardianceEmpagliflozin33$46,914
XareltoRivaroxaban29$39,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$36,112
EliquisApixaban30$33,091
ProliaDenosumab18$31,402
Repatha SureclickEvolocumab14$18,518
WegovySemaglutide12$18,156
MounjaroTirzepatide15$17,619
Atorvastatin Calcium586$5,746
Rosuvastatin Calcium489$4,938
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,272
Levothyroxine Sodium333$2,986
Losartan Potassium321$2,523
Omeprazole178$2,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$271$111,64757 claims
Johnson & JohnsonXarelto$13$39,90229 claims
GSKTrelegy Ellipta$68$36,11225 claims
AmgenProlia$871$31,40218 claims
Lilly USA, LLCMounjaro$187$17,61915 claims
AbbVieSynthroid$24$1,00321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →